BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial
Dec 8, 2020
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44%, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25% in the size of their tumors,” CNS Pharmaceuticals CEO John Climaco told the webinar audience.
To view the full article, visit https://ibn.fm/UGq02
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
57 Things You’ll Want Before Holiday Travel Begins
And you're thinking about a million different things besides the personal item for the plane. View Entire Post ›
If You’re A Bit Of A Chaos Traveler, You Need These 34 Products More Than Anyone
Come here, fellow walking messes. It's time to invest in a slim wallet tracker and some shoe bags for your dirty sneaks. View Entire Post ›
How The Clifford Clinic approaches Hifu skin lifting for a more defined face and jawline
[The content of this article has been produced by our advertising partner.] A softer jawline or the first signs of jowling can prompt a deceptively simple question: can the face look firmer without surgery? The answer starts with understanding what has changed, rather than choosing a treatment by name. For people with mild to moderate skin laxity, high-intensity focused ultrasound, or Hifu, is one non-surgical face-lifting option. It delivers focused energy beneath the skin to encourage tissue...
33 Travel Products That'll Make You Feel Like A Seasoned Pro On Your Next Trip
TSA is printing up your certificate right now. View Entire Post ›
27 Things Reviewers Have Worn On Their Beach Vacations
If you don't have a beach vacation booked before reading this, you might have one booked by the time you're done. View Entire Post ›
Sri Lankan writer Nifraz Rifaz’s debut novel confronts Islamophobia after Easter bombings
On September 22, after a five-year trial, 15 men from Sri Lanka’s minority Muslim community were convicted and sentenced to 200 to 260 years in prison each for their involvement in the 2019 Easter bombings. The coordinated suicide attacks on luxury hotels and Christian places of worship on April 21, 2019, remain one of the deadliest terror incidents in the island nation’s history, claiming more than 250 lives. While the devastation and subsequent investigations were covered widely in the global...
A scene out of a dream: Fish dance all night
The fish lantern night parade is a must-see for visitors to the villages near Huangshan in Anhui Province.
With Michelin’s Green Star gone, Hong Kong seeks to redefine sustainable dining
David Toutain witnessed the birth of the Michelin Green Star in 2020. His eponymous restaurant in Paris was among the first to be awarded while Feuille, his Hong Kong outpost, secured one within a year of its 2023 opening. But even when Michelin quietly retired the award this year, he still never understood exactly how it was assessed. “I have no idea,” he says. “I don’t know the rules. I don’t know anything about it, to be very honest.” His confusion points to a larger problem. The Green Star...
‘Hong Kong would be impossible.’ Why the newest Fotografiska photo museum is in Shenzhen
Contemporary photography museum Fotografiska’s newest outpost in Shenzhen is strikingly different from its original venue in Stockholm, Sweden – in the former customs building on the Stadsgardshamnen waterfront – or its Shanghai location, which opened in 2023 inside the Guang San Warehouse. In Shenzhen, a technological metropolis where sleek high-rises and futuristic cultural venues continue to emerge, the museum integrates into the modern urban landscape with a crisp white rectangular facade...
Montreal borough tightens rules on e-scooters as youth injuries skyrocket
The Montreal borough of Saint-Laurent has adopted a new bylaw banning electric scooters and other motorized personal mobility devices in public areas that fall within its jurisdiction. They're still allowed on bike paths and streets where the maximum speed limit is less than 50 km/h.
Could this 93-year-old sprinter's muscles hold clues to healthy aging? Scientists think so
At 93, Italian sprinter Emma Mazzenga is giving scientists a rare look at just how much of the physical decline we associate with aging may not actually be inevitable.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.